Mireille Hamparian, MD
Ophthalmology · Glendale, CANPI 1710969506
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AstraZeneca at 42.7% of the total. Reporting peaked in 2020 at $24,178 and has fallen 93.3% since, to $1,615 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $196.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Sight Sciences, Inc.$25K
- AbbVie$4K
- Alcon$3K
- Sanofi US Services Inc.$700
- Bausch & Lomb Americas Inc.$564
- plus $4K from 27 others
Across 12 payments — averaging $9745.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$86K
- Rxsight Inc$20K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Astrazeneca UK Limited$1K
What the payments were for
- Consulting fees$31,32548%
- Speaking & faculty fees$22,02834%
- Travel & lodging$7101%
- Food & beverage$10,23716%
- Education$440%
- Gifts$1290%
- Entertainment$2100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $27,625 |
| Sight Sciences, Inc. | 58 | $24,771 |
| AbbVie(2 entities) | 38 | $4,299 |
| Alcon | 43 | $2,636 |
| Sanofi US Services Inc. | 1 | $700 |
| Bausch & Lomb Americas Inc. | 20 | $564 |
| Novartis | 34 | $543 |
| Amgen(2 entities) | 22 | $340 |
| Lumenis BE Inc | 1 | $289 |
| NEW World Medical,inc. | 2 | $268 |
| Shire North American Group Inc | 7 | $260 |
| Optos, Inc. | 7 | $248 |
| Sun Pharmaceutical Industries Inc. | 10 | $240 |
| Biotissue Holdings Inc. | 6 | $227 |
| Rxsight Inc | 5 | $225 |
| Tarsus Pharmaceuticals, Inc. | 12 | $216 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $177 |
| Dompe US, Inc. | 7 | $152 |
| Aerie Pharmaceuticals, Inc. | 7 | $137 |
| Oyster Point Pharma, Inc. | 5 | $104 |
| Harrow Eye, LLC | 4 | $100 |
| Carl Zeiss Meditec, Inc. | 3 | $99 |
| Thea Pharma Inc. | 5 | $97 |
| Ivantis, Inc | 3 | $58 |
| Kala Pharmaceuticals, Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Glaukos Corporation | 1 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Nova Eye, Inc. | 1 | $36 |
| Genentech USA, Inc. | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Boston Scientific | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$24,047
- BIVV020$700
- Centurion$688
- M22$289
- NGENUITY$289
- Clareon$275
- AcrySof$267
- Luxor$261
- RXSIGHT INJECTOR HANDPIECE$142
- RXSIGHT CONTACT LENS$142
- RXSIGHT INJECTOR CARTRIDGE$142
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$142
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$142
- Kahook Dual Blade$138
- Clearpath$138
- Ahmed Glaucoma Valve$138
- Streamline$138
- TRYPTYR$125
- MIEBO$125
- Prokera$119
How this compares
$64,683 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 263 | $201,509 |
| RestasisCyclosporine | 293 | $193,227 |
| Cyclosporine | 556 | $181,370 |
| LumiganBimatoprost | 472 | $175,220 |
| ProlensaBromfenac Sodium | 362 | $127,342 |
| Prednisolone Acetate | 1,194 | $39,948 |
| MieboPerfluorohexyloctane/Pf | 47 | $39,554 |
| CombiganBrimonidine Tartrate/Timolol | 114 | $30,031 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $27,360 |
| Fluorometholone | 294 | $24,388 |
| VyzultaLatanoprostene Bunod | 55 | $22,690 |
| Bromfenac Sodium | 87 | $17,970 |
| RhopressaNetarsudil Mesylate | 47 | $16,084 |
| Alphagan PBrimonidine Tartrate | 54 | $15,286 |
| CequaCyclosporine | 24 | $15,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $4,299 | $413,763933 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $564 | $263,753365 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Alrex, Loteprednol Etabonate | $177 | $137,066400 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $137 | $43,444113 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $240 | $15,20124 claims |
| NovartisTravatan Z | $543 | $7,55814 claims |
| Thea Pharma Inc.Iyuzeh | $97 | $5,46519 claims |
| AlconSimbrinza | $2,636 | $4,47423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Glendale
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.